ストックスクリーナーアプリを入手
1.60
0.00%
0.00
アフターアワーズ：
1.64
0.04
+2.50%
前日終値:
$1.60
開ける：
$1.57
24時間の取引高:
182.04K
Relative Volume:
1.57
時価総額：
$118.77M
収益：
-
当期純損益:
$-4.67M
株価収益率:
-25.20
EPS:
-0.0635
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-6.98%
1か月 パフォーマンス:
-20.40%
6か月 パフォーマンス:
-45.21%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.57
$1.70
1週間の範囲:
$1.5006
$1.94
52週間の値動き範囲:
$1.43
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Compare MENS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
1.60 | 118.77M | 0 | -4.67M | 0 | -0.0635 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jyong Biotech Ltd (MENS) 最新ニュース
Certain Ordinary Shares of Jyong Biotech Ltd. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
JYONG BIOTECH LTD (MENS) Stock Chart - ChartMill
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview - digitalmore.co
Jyong Biotech outlines FDA approval path for botanical drug Botreso® targeting benign prostatic hyperplasia. - Pluang
12M Americans have BPH; one biotech is testing a plant-based option - Stock Titan
Jyong Biotech (MENS) Remains Range-Bound as Price Consolidates Near SupportPut Flow Alert - The Legal Advocate
Jyong Biotech Ltd. (MENS) Surges 3.37% as Buyers Defend Key Support LevelTake Profit Levels - The Legal Advocate
Jyong Biotech Ltd. (MENS) Shows Resilience: Uptick from Key Support ZoneImbalance Zone - The Legal Advocate
Jyong Biotech Ltd. (MENS) Gains 3.37% as Technical Support Holds, Resistance in FocusIV Rank - Newser
Jyong Biotech Ltd. (MENS) Stabilizes Near Key Support After Modest UptickIchimoku TK Cross - Newser
MENS Stock Price, Quote & Chart | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 - marketscreener.com
Jyong Biotech (NASDAQ: MENS) flags Botreso FDA hurdles and $19.4M judgment - Stock Titan
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year Ended December 31, 2025 - Quiver Quantitative
DXS INTERNATIONAL PLC (AQSE: DXSP): Issue of New Shares and Notification of Director / PDMR Dealings - Weekly Voice
Jyong Biotech Ltd. Auditor Raises 'Going Concern' Doubt - marketscreener.com
What Jyong Biotech (MENS) management focus reveals about priorities (Risk Aversion) 2026-05-11Crowd Sentiment Stocks - Newser
Jyong Biotech Delays Annual 20-F (Yearly Report) - The Globe and Mail
Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio - The Manila Times
Jyong Biotech Updates Market Access Strategy for Innovative - GlobeNewswire
Short Interest in Jyong Biotech Ltd. (NASDAQ:MENS) Decreases By 43.2% - MarketBeat
CEO-linked entities report 33.34% Jyong Biotech (MENS) stake via trust - Stock Titan
Jyong Biotech (MENS) Management Strategy | Q1 2025: Earnings ReportPre Earnings - Cổng thông tin điện tử tỉnh Lào Cai
Who Backs Jyong Biotech (MENS) Stock (Risk Aversion) 2026-04-20Investment Picks - Cổng thông tin điện tử tỉnh Lào Cai
Ming Tsan Hsu Net Worth (2026) - GuruFocus
Pang Chieh Chi Net Worth (2026) - GuruFocus
Hung Shu Fan Net Worth (2026) - GuruFocus
Feng Lin Hsu Net Worth (2026) - GuruFocus
Fu Feng Kuo Net Worth (2026) - GuruFocus
Jyong Biotech Ltd. (NASDAQ:MENS) Sees Significant Decrease in Short Interest - MarketBeat
Jyong Biotech Ltd. Live Share Prices and Trades. MENS.US Live Streaming Share Prices. - London South East
Jyong Biotech (NASDAQ: MENS) CFO ZHANG WEI files initial Form 3 - Stock Titan
Wei (vivi) Zhang Net Worth (2026) - GuruFocus
MENS Options Volatility — NASDAQ:MENS - TradingView
MENS Options Chain — NASDAQ:MENS - TradingView
MENS News | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
Jyong Biotech (MENS) CEO Kuo reports 25,349,500-share indirect stake on Form 3 - Stock Titan
Is Jyong Biotech (MENS) Stock Rebounding | Price at $2.47, Up 0.82%Bull Flag - newsline.com
MENS PE Ratio & Valuation, Is MENS Overvalued - Intellectia AI
Director of Jyong Biotech (MENS) files Form 3 showing 3,000 common shares - Stock Titan
Director Hsu Feng-Lin reports 3,000 Jyong Biotech (MENS) shares on Form 3 - Stock Titan
Director at Jyong Biotech (MENS) discloses holding 3,000 shares - Stock Titan
Jyong Biotech (MENS) director Fan Hung-Shu files initial Form 3 - Stock Titan
Jyong Biotech (MENS) director files Form 3 with no insider trades - Stock Titan
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 22.7% in March - Defense World
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2 - The Manila Times
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS-2 - Bitget
Jyong Biotech Ltd (MENS) 財務データ
収益
当期純利益
現金流量
EPS
2.60%
0.94%
大文字化:
|
ボリューム (24 時間):